We investigate the use of syndecan-1 peptide (SDC1) to actively target a liposomal formulation of echinomycin to insulin-like growth factor receptor 1 (IGF1-R) for treatment of pancreatic cancer. Here, SDC1 is linked to pancreatic neoplasm.